文章核心观点 - 公司是一家临床阶段生物技术公司,正在开发新型、首创的异位性离子通道调节剂,用于治疗严重的中枢神经系统(CNS)疾病 [1] - 公司将参加H.C. Wainwright 26th Annual Global Investment Conference,公司CEO将在会上进行公司介绍演讲 [1][2] - 公司与默克公司有战略合作关系,正在开发两种用于治疗阿尔茨海默病认知缺陷和其他CNS疾病的早期临床试验药物 [4] - 公司还有一些针对Kv3.1/3.2和Nav1.7/1.8离子通道的临床前资产,正在开发用于高未满足医疗需求的CNS疾病 [4] 公司概况 - 公司是一家临床阶段生物技术公司,总部位于澳大利亚阿德莱德和美国剑桥 [1] - 公司专注于开发新型、首创的异位性离子通道调节剂,用于治疗严重的中枢神经系统(CNS)疾病 [1][4] - 公司的领先药物候选物BNC210是一种口服、专有的选择性α7烟碱乙酰胆碱受体负性异位调节剂,用于治疗社交焦虑障碍(SAD)和创伤后应激障碍(PTSD) [4] - 公司与默克公司有战略合作关系,正在开发两种用于治疗阿尔茨海默病认知缺陷和其他CNS疾病的早期临床试验药物 [4] - 公司还有一些针对Kv3.1/3.2和Nav1.7/1.8离子通道的临床前资产,正在开发用于高未满足医疗需求的CNS疾病 [4] 会议参与情况 - 公司将参加H.C. Wainwright 26th Annual Global Investment Conference,会议将于2024年9月9-11日以线上和线下的方式举行 [1][2] - 公司CEO Spyros Papapetropoulos博士将在会上进行公司介绍演讲,演讲将于9月9日7:00 AM ET开始提供点播 [1][2] - 公司管理层将在会议期间接受一对一会议,有兴趣的投资者应联系H.C. Wainwright的代表 [2] - 演讲录像将在可用时发布在公司网站的投资者中心"活动"页面 [2]

Successful End-of-Phase 2 (EoP2) meeting with U.S. Food and Drug Administration (FDA) provides a potential path to New Drug Application (NDA) submission for BNC210 for post-traumatic stress disorder (PTSD) with a single Phase 3 trialCompany received favorable FDA feedback on the Phase 3 study design and safety monitoring plans required for registrationCompany plans to initiate the Phase 3 program in Q4 2024A conference call and webcast presentation to discuss the outcomes will be held today at 8:00 a.m. ET, ...

Successful End-of-Phase 2 (EoP2) meeting with U.S. Food and Drug Administration (FDA) provides a potential path to New Drug Application (NDA) submission for BNC210 for post-traumatic stress disorder (PTSD) with a single Phase 3 trialCompany received favorable FDA feedback on the Phase 3 study design and safety monitoring plans required for registrationCompany plans to initiate the Phase 3 program in Q4 2024A conference call and webcast presentation to discuss the outcomes will be held today at 8:00 a.m. ET, ...

ADELAIDE, Australia and CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will provide a corporate update and discuss the outcomes of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration reg ...

ADELAIDE, Australia and CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will provide a corporate update and discuss the outcomes of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration re ...

Topline results are expected in Q3 2025 ADELAIDE, Australia and CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the initiation of patient screening for the Phase 3 AFFIRM-1 trial evaluating the safety and efficacy of BNC210 ...

Topline results are expected in Q3 2025 ADELAIDE, Australia and CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the initiation of patient screening for the Phase 3 AFFIRM-1 trial evaluating the safety and efficacy of BNC210 ...

ADELAIDE, Australia and CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first- in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Spyridon "Spyros" Papapetropoulos, M.D., PhD, President and Chief Executive Officer of Bionomics will be giving an oral presentation and prese ...

ADELAIDE, Australia and CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first- in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Spyridon "Spyros" Papapetropoulos, M.D., PhD, President and Chief Executive Officer of Bionomics will be giving an oral presentation and prese ...

BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications. BNC210's emerging safety and tolerability profile continues to support its differentiation over approved, available, and experimental psychoactive treatments. Bionomics will meet with the U.S. Food & Drug Administration (FDA) to discuss BNC210's registrational program in PTSD by end of the se ...